PT UBC Medical Indonesia Tbk (IDX:LABS)
Indonesia · Delayed Price · Currency is IDR 145.00
-6.00 (-3.97%)
May 26, 2026, 4:04 PM WIB
IDX:LABS Revenue
PT UBC Medical Indonesia Tbk had revenue of 40.02B IDR in the quarter ending March 31, 2026, with 19.60% growth. This brings the company's revenue in the last twelve months to 205.85B, up 35.11% year-over-year. In the year 2025, PT UBC Medical Indonesia Tbk had annual revenue of 199.30B with 34.99% growth.
Revenue (ttm)
205.85B
Revenue Growth
+35.11%
P/S Ratio
2.78
Revenue / Employee
3.81B
Employees
54
Market Cap
572.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 199.30B | 51.66B | 34.99% |
| Dec 31, 2024 | 147.64B | 10.94B | 8.00% |
| Dec 31, 2023 | 136.70B | 43.41B | 46.53% |
| Dec 31, 2022 | 93.29B | -36.67B | -28.22% |
| Dec 31, 2021 | 129.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PT Kalbe Farma Tbk. | 36.21T |
| PT Siloam International Hospitals Tbk | 13.09T |
| PT Mitra Keluarga Karyasehat Tbk | 5.45T |
| PT. Penta Valent Tbk | 3.58T |
| PT Sejahteraraya Anugrahjaya Tbk | 2.64T |
| PT Itama Ranoraya Tbk | 1.10T |
| PT Kedoya Adyaraya Tbk | 490.35B |
| PT Indofarma Tbk | 206.24B |